Riverbridge Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20.3M | Sell |
133,627
-89,107
| -40% | -$13.5M | 0.33% | 81 |
|
|
2025
Q1 | $33.5M | Sell |
222,734
-16,654
| -7% | -$2.51M | 0.54% | 66 |
|
|
2024
Q4 | $44.2M | Sell |
239,388
-27,059
| -10% | -$5M | 0.6% | 61 |
|
|
2024
Q3 | $52.5M | Sell |
266,447
-22,825
| -8% | -$4.5M | 0.7% | 54 |
|
|
2024
Q2 | $59.8M | Sell |
289,272
-14,506
| -5% | -$3M | 0.81% | 47 |
|
|
2024
Q1 | $82.3M | Buy |
303,778
+3,088
| +1% | +$837K | 1% | 38 |
|
|
2023
Q4 | $71.1M | Sell |
300,690
-14,368
| -5% | -$3.4M | 0.89% | 43 |
|
|
2023
Q3 | $61.7M | Sell |
315,058
-6,122
| -2% | -$1.2M | 0.84% | 43 |
|
|
2023
Q2 | $67.5M | Buy |
321,180
+22,186
| +7% | +$4.66M | 0.85% | 45 |
|
|
2023
Q1 | $60.3M | Sell |
298,994
-1,814
| -0.6% | -$366K | 0.85% | 44 |
|
|
2022
Q4 | $65.5M | Sell |
300,808
-18,412
| -6% | -$4.01M | 0.98% | 34 |
|
|
2022
Q3 | $62.8M | Buy |
319,220
+87,669
| +38% | +$17.3M | 0.93% | 38 |
|
|
2022
Q2 | $49.5M | Sell |
231,551
-27,470
| -11% | -$5.88M | 0.79% | 47 |
|
|
2022
Q1 | $73.6M | Buy |
259,021
+88,183
| +52% | +$25M | 0.83% | 45 |
|
|
2021
Q4 | $64.4M | Buy |
170,838
+5,553
| +3% | +$2.09M | 0.64% | 54 |
|
|
2021
Q3 | $68.2M | Sell |
165,285
-751
| -0.5% | -$310K | 0.68% | 57 |
|
|
2021
Q2 | $61.4M | Buy |
166,036
+10,657
| +7% | +$3.94M | 0.62% | 57 |
|
|
2021
Q1 | $45M | Buy |
+155,379
| New | +$45M | 0.51% | 65 |
|